Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Change

3 Jul 2023 07:02

RNS Number : 6479E
Tate & Lyle PLC
03 July 2023
 

Directorate Change

 

Tate & Lyle PLC (Tate & Lyle) announces that Dr Gerry Murphy has decided to step down as Chair of the Board of Tate & Lyle, a position he has held for more than six years to take up the position of Chair of the Board of Tesco plc. Dr Murphy will remain Chair of Tate & Lyle until 1 September 2023.

 

The Board has begun a process to appoint a successor to Dr Murphy. Mr Paul Forman, Senior Independent Director, is leading this process and a further announcement will be made in due course.

 

As previously announced, Mr Forman was due to retire from the Tate & Lyle Board at the AGM on 27 July 2023. In light of Dr Murphy's decision, Mr Forman will continue as a non-executive director and as Senior Independent Director to allow time to complete the search process. The Board will therefore propose an additional resolution at the AGM in respect of Mr Forman's annual re-election as a non-executive director, in accordance with applicable corporate governance guidance. When the search for a new Chair has been concluded, Mr Forman will retire from the Board and Kim Nelson will take up the position of Senior Independent Director, as previously announced.

 

Pending the appointment of a new Chair, the Board has appointed Warren Tucker as Interim Chair of Tate & Lyle from 1 September 2023. Warren is currently Chair of the Audit Committee and will continue in this role during this interim period.

 

Nick Hampton, Chief Executive said: "Gerry has made a significant contribution to Tate & Lyle over the last six years. He has led the Board expertly through a major strategic transformation to reposition Tate & Lyle as a growth focussed global speciality food and beverage solutions business meeting growing consumer demand for healthier and tastier food and drink. It has been a pleasure to work alongside him. On behalf of the Board, we thank him for his leadership and wish him well in his new role."

 

Gerry Murphy, said: "It has been a privilege to serve as Chair of Tate & Lyle for the last six years, a company which I have known since my early years as a food scientist. Tate & Lyle, with its clear focus and ambitious purpose, its outstanding leadership team led by Nick Hampton and a very committed Board of Directors, is well-positioned to capture the growth opportunities that lie ahead. I would like to thank my fellow directors, and all my friends and colleagues in the Tate & Lyle family around the world for their support and stimulation since the day I joined the company in January 2017."

 

This announcement is made pursuant to LR 9.6.11R.

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383

 

 

About Tate & Lyle: Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, fortification, and mouthfeel, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverage, dairy, bakery and snacks, and soups, sauces, and dressings.

We have more than 3,600 employees working in 58 locations across the world. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue totalled £1.75 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin, Facebook or YouTube.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASSUSUEEDSELW
Date   Source Headline
2nd Dec 202412:30 pmRNSTotal Voting Rights
29th Nov 20245:41 pmRNSTransaction in Own Shares
28th Nov 20245:21 pmRNSTransaction in Own Shares
27th Nov 20245:31 pmRNSTransaction in Own Shares
26th Nov 20245:48 pmRNSTransaction in Own Shares
26th Nov 20242:30 pmRNSHolding(s) in Company
25th Nov 20245:09 pmRNSTransaction in Own Shares
22nd Nov 20245:28 pmRNSTransaction in Own Shares
21st Nov 20245:24 pmRNSTransaction in Own Shares
20th Nov 20245:44 pmRNSTransaction in Own Shares
20th Nov 20244:30 pmRNSHolding(s) in Company
19th Nov 20245:33 pmRNSTransaction in Own Shares
19th Nov 20243:15 pmRNSHolding(s) in Company
19th Nov 20243:00 pmRNSHolding(s) in Company
18th Nov 20245:20 pmRNSTransaction in Own Shares
18th Nov 20244:00 pmRNSHolding(s) in Company
18th Nov 20248:30 amRNSDirector/PDMR Shareholding
18th Nov 20248:00 amRNSAdmission of New Tate & Lyle Shares
15th Nov 20245:30 pmRNSTransaction in Own Shares
15th Nov 20243:13 pmRNSCompletion of Combination Tate & Lyle and CP Kelco
14th Nov 20245:48 pmRNSTransaction in Own Shares
13th Nov 20245:16 pmRNSTransaction in Own Shares
12th Nov 20245:45 pmRNSTransaction in Own Shares
11th Nov 20245:37 pmRNSTransaction in Own Shares
8th Nov 20245:29 pmRNSTransaction in Own Shares
7th Nov 20245:31 pmRNSTransaction in Own Shares
7th Nov 20247:00 amRNSHalf-year Report
6th Nov 20245:44 pmRNSTransaction in Own Shares
5th Nov 20245:20 pmRNSTransaction in Own Shares
5th Nov 20241:00 pmRNSHolding(s) in Company
4th Nov 20245:28 pmRNSTransaction in Own Shares
1st Nov 20245:44 pmRNSTransaction in Own Shares
1st Nov 202412:15 pmRNSTotal Voting Rights
31st Oct 20245:28 pmRNSTransaction in Own Shares
30th Oct 20245:33 pmRNSTransaction in Own Shares
29th Oct 20245:27 pmRNSTransaction in Own Shares
28th Oct 20245:40 pmRNSTransaction in Own Shares
28th Oct 20244:30 pmRNSHolding(s) in Company
25th Oct 20245:25 pmRNSTransaction in Own Shares
24th Oct 20245:31 pmRNSTransaction in Own Shares
23rd Oct 20245:19 pmRNSTransaction in Own Shares
23rd Oct 202411:00 amRNSHolding(s) in Company
22nd Oct 20245:28 pmRNSTransaction in Own Shares
22nd Oct 202412:45 pmRNSTotal Voting Rights
21st Oct 20245:36 pmRNSTransaction in Own Shares
18th Oct 20245:46 pmRNSTransaction in Own Shares
17th Oct 20245:40 pmRNSTransaction in Own Shares
16th Oct 20245:20 pmRNSTransaction in Own Shares
15th Oct 20245:23 pmRNSTransaction in Own Shares
14th Oct 20245:29 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.